Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00109083 · ClinicalTrials.gov registry record · Phase 2

A Study of the Efficacy of RWJ-333369 in the Prevention of Migraine

A Phase 2 study of Migraine Headaches, sponsored by SK Life Science.

Completed
Registry status
Phase 2
Development phase
300
Enrollment target
20
Study locations

NCT00109083: Completed Phase 2 study of Migraine Headaches, sponsored by SK Life Science.

NCT00109083 is a Phase 2 study of Migraine Headaches that has completed, run by SK Life Science. The registered enrollment target is 300 participants, above the 61-participant average among 4 other Migraine Headaches trials with a reported enrollment target (392% higher). The trial reports 20 study locations across 16 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00109083, a Phase 2 study of Migraine Headaches, has completed, sponsored by SK Life Science.

COMPLETED
Registry status
Phase 2
Development phase
300 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to evaluate whether RWJ-333369 is a safe and effective treatment in reducing the number of migraine headaches when added to a person's usual medications for acute migraine headache relief.

Conditions Studied

Migraine Headaches

Interventions

  • DRUG RWJ-333369

Study Locations (20)

Florida

  • - Miami
  • - St. Petersburg

Massachusetts

  • - Brockton
  • - Springfield

Ohio

  • - Cincinnati
  • - Mogadore

Texas

  • - Austin
  • - Houston

Alabama

  • - Northport

Arizona

  • - Phoenix

Arkansas

  • - Little Rock

California

  • - Berkeley

Trial Details

FieldValue
Enrollment Target 300 participants
Start Date 2002-03
Est. Completion 2006-02
Phase Phase 2
SK Life Science

25 total trials

What the finished NCT00109083 record still lists

NCT00109083 is an interventional study that assigns participants to a tested intervention. The registered 300 participants enrollment target is mid-sized for trials with a published cap, above the 61-participant average among 4 other Migraine Headaches trials with a reported enrollment target (392% higher).

The record links to 1 condition, with Migraine Headaches appearing as the primary indexed condition, and to 1 intervention - of which RWJ-333369 is the first listed.

NCT00109083 names 20 study sites across 16 states, led by Florida, Massachusetts, Ohio.

Frequently Asked Questions

What is clinical trial NCT00109083 about?

NCT00109083 is a clinical study titled "A Study of the Efficacy of RWJ-333369 in the Prevention of Migraine". The purpose of this study is to evaluate whether RWJ-333369 is a safe and effective treatment in reducing the number of migraine headaches when added to a person's usual medications for acute migraine headache relief.

What is the current status of trial NCT00109083?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 300 participants. The study started on 2002-03. Estimated completion is 2006-02.

What conditions does trial NCT00109083 study?

This clinical trial studies the following conditions: Migraine Headaches.

What interventions are being tested in trial NCT00109083?

The interventions under investigation include: RWJ-333369 (DRUG).

Who is sponsoring clinical trial NCT00109083?

This trial is sponsored by SK Life Science, which has 25 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00109083 being conducted?

This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Migraine Headaches

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00353483 · 300 participants

    Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells

  • NCT00588185 · 300 participants · NA

    [18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer

  • NCT00682032 · 300 participants · NA

    The Effect of Beta-glucan in Non-Small Cell Lung Cancer

  • NCT00870064 · 300 participants · NA

    The Treatment of Type I Open Fractures in Pediatrics

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT00109083, the US trial registry maintained by the National Library of Medicine. NCT00109083 (mid enrollment · wide site footprint · completed) retrieved and formatted by PlainTrial, see methodology.